Newsroom
Sorted by: Latest
-
Secretome Therapeutics to Present at the 2026 J.P. Morgan Healthcare Conference
PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced that it will present at the 2026 J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco, California. Secretome Therapeutics’ presentation is scheduled for Thursday, January 15, 2026, from 9:00 AM to 9:25 AM (PT). During the presentation, the company w...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: SNB FUNDING LIMITED AUD 20,000,000.00 MATURING: 27-Jun-2033 ISIN: XS2642669043 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 29-Dec-2025 TO 27-Mar-2026 HAS BEEN FIXED AT 5.49 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 27-Mar-2026 WILL AMOUNT TO: AUD 2,647.23 PER AUD 200,000.00 DENOMINATION ...
-
European Union Veterinary Pharmacovigilance Introductory Training Course: Practical Guidance and Basic Training for All Those Working in Drug Safety (Mar 9th - Mar 10th, 2026) - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Introduction to Veterinary Pharmacovigilance Training Course (Mar 9th - Mar 10th, 2026)" training has been added to ResearchAndMarkets.com's offering. This two-day event has been designed to provide an essential overview of veterinary pharmacovigilance and will offer practical guidance and basic training for all those working in drug safety in the EU. Our experienced trainer will clarify roles and responsibilities, explain commonly used terminology and take partici...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 24.12.2025 SDVI.LN IE000YVOQ2A3 40,361.00 USD 1,076,517.63 26.672 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust SMID Rising Dividend Achievers UCITS ETF 24.12.2025 SDVY.LN IE0001R850E1 10,754,007.00 USD 251,858,334.53 23.420 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Growth Strength UCITS ETF 24.12.2025 FTGS.LN IE000YZLMXT9 25,002.00 USD 561,854.21 22.472 ...
-
Citibank UK Regulatory Announcement: FRN Variable Rate Fix
LONDON--(BUSINESS WIRE)-- Re: First Abu Dhabi Bank P.J.S.C. AUD 35,000,000.00 MATURING: 29-Jun-2026 ISIN: XS2358731177 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 29-Dec-2025 TO 30-Mar-2026 HAS BEEN FIXED AT 4.48 PCT DAY BASIS: ACTUAL/365(PROP) INTEREST PAYABLE VALUE 30-Mar-2026 WILL AMOUNT TO: AUD 11,169.32 PER AUD 1,000,000.00 DENOMINATION ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - February 24.12.2025 GFEB.LN IE000X8M8M80 700,002.00 USD 25,978,231.49 37.112 ...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest S&P 500 Dividend Aristocrats Target Income UCITS ETF 24.12.2025 KNG.LN IE000SNMGYT5 200,002.00 USD 4,105,236.16 20.526 ...
-
Oncodesign Precision Medicine et Navigo Proteins annoncent la fin de leur collaboration dans le développement de radiothéranostiques
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ; Mnémonique : ALOPM), entreprise biopharmaceutique spécialisée en médecine de précision pour le traitement des cancers résistants et métastatiques, et Navigo Proteins GmbH (Halle, Allemagne) entreprise biopharmaceutique spécialisée dans la découverte et le développement de nouvelles approches de médecine de précision basées sur la plateforme technologique Affilin®, annoncent conjointement...